Navigation Links
Researchers find drug-eluting stents safe, effective for PCI in diabetics
Date:9/21/2009

SAN FRANCISCO, CA ─ SEPTEMBER 21, 2009 Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

The study, "The Effect of Drug-Eluting Stents on Clinical and Angiographic Outcomes in Diabetic Patients: Multicenter Registry in Asia," compared the safety and efficacy of sirolimus (SES), paclitaxel (PES), zotarolimus ( ZES), biolimus A9 (BES) and everolimus-eluting (EES) stents on the outcome of percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM).

The study will be presented as a poster abstract (TCT-363) on Tuesday, September 22 between 8:00 a.m. and 10:00 a.m. in Hall D of The Moscone Center. Sunao Nakamura, MD, lead investigator for the study, will report on the results of the investigations. Dr. Nakamura is Vice President and Director of the Cardiovascular Center at New Tokyo Hospital as well as Clinical and Visiting Professor of Kumamoto University in Matsudo, Japan.

The investigation consisted of a prospective analysis of 1,373 patients with DM treated with different drug-eluting stents (508 SES, 420 PES, 204 ZES, 120 BES and 121 EES) in six high-volume Asian centers. The study endpoints were the incidence of MACE at 30 days, the restenosis rate at 9 months and target lesion revascularization (TLR) at 9 months.

The incidence of MACE with this study cohort was 0.8% in patients receiving SES, 1.2% in PES, 1.0% in ZES, 0.8% in BES and 0.0% in EES. The restenosis rate at 9 months was 7.9% for those receiving SES, 12.6% for PES, 16.2% for ZES, 5.0% for BES and 6.7% for EES. TLR at 9 months was 6.5% in patients receiving SES, 10.7% with PES, 13.7% with ZES, 5.0% with BES and 4.1% with EES.

The researchers concluded that the use of drug-eluting stents in patients with DM was safe with low acute complications. Further, patients treated with SES, BES and EES showed a lesser rate of restenosis when compared with other drug-eluting stents.


'/>"/>

Contact: Judy Romero
jromero@crf.org
347-407-2774
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Researchers Propose Improved Cervical Cancer Screening
2. Researchers Perfect the View of Heart Disease
3. Mayo Clinic researchers lead national trial testing new treatment for chronic, severe indigestion
4. Indiana U medical researchers boost research and jobs with stimulus legislation grants
5. Canadian researchers discover the first-ever link between intelligence and curiosity
6. MUSC Researchers Concerned About Online Drug Availability
7. UCLA researchers develop biomarker for rapid relief of major depression
8. UCSB researchers develop drug delivery system using nanoparticles and lasers
9. University of Arizona researchers seek safer cystic fibrosis test
10. UAB researchers find TB-prevention therapy is cost-effective option
11. U of T researchers identify protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... The Global Wellness Summit (GWS) today announced that ... offerings of Europe, a continent that pioneered the medical/wellness concept for the world. , ... in medical wellness, including Henri Chenot, Founder of the Chenot Group, which operates wellness ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Casa Velas, an ... properties of precious stones to complement its new wellness suites . The two ... and feature a plethora of special services and insuite amenities, from a custom soap ...
(Date:5/25/2016)... ... May 25, 2016 , ... America Walks , a national advocacy ... of the University of Pittsburgh Graduate School of Public Health , has been ... and 24 other advocates from around the country to participate in a four-month training ...
(Date:5/25/2016)... ... 25, 2016 , ... "FCPX LUT Intense allows users to cycle through different ... - CEO of Pixel Film Studios. , With the FCPX LUT Intense ... grades to their footage. A LUT is a Lookup Table that contains a mathematical ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Consumer access to ... early June 2016, Kashi®, a maker of whole grain cereals and other plant-based foods, ... Transitional ingredient: hard red winter wheat processed by Hesco/Dakota Organic Products. , The ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... LAWRENCEVILLE, N.J. , May 24, 2016 /PRNewswire/ ... an oncology drug development company, today provided an ... Ib dose escalating clinical trial combining GEN-1, the ... for the treatment of newly-diagnosed patients with advanced ... by interval debulking surgery.  GEN-1 is an IL-12 ...
(Date:5/24/2016)... May 24, 2016 Los ... terapia del mundo, introduce catéteres para la intervención ... OrbusNeich, una compañía global especializada en el suministro ... expandido su cartera incluyendo productos para tratar la ... Scoreflex™ PTA son los dispositivos de primera entrada ...
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to ... patients on a global scale. Medical professionals from Europe ... and the US have already signed up for the app, ... totally secure environment. Education  "Imagine a doctor ... a surgeon at Harvard to treat a bomb victim via live ...
Breaking Medicine Technology: